Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry p…
An institutional-grade, numbers-driven thesis on LQDA — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Liquidia Corporation (LQDA) 71/100 with a 12-month base-case forecast of $98.11 — +31.8% versus the current price of $74.44. Liquidia Corporation trades at $74.44 in the Healthcare sector, with a market capitalisation of $6.62B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for LQDA is $98.11, implying +31.8% versus the current price. The model's 12-month scenario range runs from $144.80 (bear) to $161.25 (bull), with a base case of $148.88.
On the fundamentals, Liquidia shows a P/E of 47.4, trailing revenue of $158.3M, revenue growth of +1031.2% YoY. This page also tracks LQDA's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
LQDA currently carries a TradersQuant composite score of 71/100, which we read as a strong composite signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $98.11 implies +31.8% from $74.44. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for LQDA is $98.11, about +31.8% versus the latest price of $74.44. Consensus is based on 7 analysts.
TradersQuant's 12-month model forecast for LQDA is a base case of $148.88, ranging from $144.80 (bear) to $161.25 (bull), an expected return of +100.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for LQDA over the next 12 months is $148.88 in the base case (bear $144.80, bull $161.25), versus today's price of $74.44. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for LQDA — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates LQDA's fair value at $98.11, implying +31.8% of expected upside versus the current price.
Liquidia does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
